 Eli Lilly and Co NYSE:LLY shares sank after it emerged that the US Food and Drug Administration FDA said needed to see more data on the companys application to accelerate approval of its potential Alzheimers disease treatment. In the complete response letter to the companys accelerated approval application, the regulator specifically requested that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab, the company said after markets closed on Thursday. 